Champions Oncology, Inc. (CSBR) has a consensus analyst rating of Buy, based on 7 analysts covering the stock. Of those, 5 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for CSBR is $12.00, representing a +109.4% upside from the current price of $5.73. Price targets range from a low of $12.00 to a high of $12.00.
